
CLAIMS

1. A compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof;



(1)

wherein

R^A is $-CH_2-CZ^1Z^2(COX)$ or $-CH=CZ^1(COX)$, Z^1 and Z^2 are each independently a hydrogen atom or a fluorine atom, X is OR^4 or NR^5R^6, R^4 is a hydrogen atom, an alkyl group having 1 - 6 carbon atoms or a substituted alkyl group having 1 - 6 carbon atoms, R^5 is a hydrogen atom, an alkyl group having 1 - 6 carbon atoms or a substituted alkyl group having 1 - 6 carbon atoms, R^6 is a hydrogen atom, an alkyl group having 1 - 6 carbon atoms, a substituted alkyl group having 1 - 6 carbon atoms, an alkylsulfonyl group having 1 - 6 carbon atoms, a substituted alkylsulfonyl group having 1 - 6 carbon atoms, an arylsulfonyl group having 6 - 10 carbon atoms or a substituted arylsulfonyl group having 6 - 10 carbon atoms;

Y is CH_2, S or O;

A-B is a carbon-carbon single bond or a carbon-carbon double bond;

a hydroxy group bonded by a wavy line is a hydroxy group having α-configuration, β-configuration or a mixed configuration of α-configuration and β-configuration;

R^1 and R^2 are each independently a hydrogen atom, an alkyl group having 1 - 3 carbon atoms or a substituted alkyl group having 1 - 3 carbon atoms;

n is an integer of 0 - 2;

R^3 is an alkyl group having 2 - 3 carbon atoms or a

cycloalkyl group having 3 - 5 carbon atoms.

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Y is CH_2.

3. The compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R^A is $-CH=CZ^1(COX)$.

4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R^A is $-CH_2-CZ^1Z^2(COX)$.

5. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein n is 1.

6. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein A-B is a carbon-carbon double bond.

7. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein R^1 is a hydrogen atom and R^2 is an alkyl group having 1 - 3 carbon atoms.

8. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R^3 is a cycloalkyl group having 3 - 5 carbon atoms.

9. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein X is OR^4.

10. A cyclodextrin clathrate compound of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9.

11. A medicament comprising the compound or a pharmaceutically

acceptable salt thereof according to any one of claims 1 to 9, or the cyclodextrin clathrate compound according to claim 10 as an active ingredient.

12. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, the cyclodextrin clathrate compound according to claim 10 or the medicament according to claim 11 for use in a prophylactic or therapeutic method of a blood flow disorder.

13. The medicament for use according to claim 12, wherein the blood flow disorder is a blood flow disorder of nerve, preferably a blood flow disorder associated with spinal canal stenosis.

14. The medicament for use according to claim 12, wherein the blood flow disorder is a blood flow disorder of peripheral artery, skin or brain, preferably a blood flow disorder of peripheral artery associated with chronic arterial occlusion or pulmonary hypertension, a blood flow disorder of skin associated with pressure ulcer or a blood flow disorder of brain associated with suppression of recurrence after cerebral infarction.

15. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 or the cyclodextrin clathrate compound according to claim 10, in the manufacture of a medicament for the prophylaxis or treatment of a blood flow disorder.

16. The use according to claim 15, wherein the blood flow disorder is a blood flow disorder of nerve, preferably a blood flow disorder associated with spinal canal stenosis.

17. The use according to claim 15, wherein the blood flow disorder is a blood flow disorder of peripheral artery, skin or brain, preferably a blood flow disorder of peripheral artery associated with chronic arterial occlusion or pulmonary hypertension, a blood flow disorder of skin associated with pressure ulcer or a blood flow disorder of brain associated with suppression of recurrence after cerebral infarction.

18. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 or the cyclodextrin clathrate compound according to claim 10, for use as a medicament.